Bioavailability is a complex process influenced by multiple factors
Evaluation of production: type II collagen, aggrecan, MMP-13 (degradation enzyme), IL-1 response
Goals of Treatment Eliminating the entire at risk mucosa Minimizing complications Minimizing recurrence, strictures and bleeding Decreasing the need for frequent surveillance To meet these objectives, the correct depth ablation should target to, but not beyond, the muscularis mucosa
Further details of the trial results will be disclosed once intellectual property rights and data protection rights are secured
Peptide amount in milligrams divided by water volume in milliliters equals concentration in milligrams per milliliter
Further reduction in injury recurrence and chronic pain